DEF 14A: Clearside Biomedical Sets Date for Annual Stockholder Meeting, Highlights Progress in Suprachoroidal Delivery

Clearside Biomedical's proxy statement highlights the company's progress in suprachoroidal drug delivery and upcoming data readout for its CLS-AX wet AMD program.

Summary

• Clearside Biomedical is holding its Annual Meeting of Stockholders on June 20, 2024.
• The company is focused on suprachoroidal delivery of therapeutics to the back of the eye.
• Clearside's SCS Microinjector has been used in thousands of patient injections and has a positive safety profile to date.
• Their first product, XIPERE, is approved for macular edema associated with uveitis.
• The company's lead clinical program, CLS-AX, targets the multi-billion-dollar market for wet AMD.
• Data readout from the CLS-AX Phase 2b ODYSSEY clinical trial is expected in the third quarter of this year.
• Clearside has multiple partnerships with biopharma companies using their SCS Microinjector.
• The company appointed Dr. Victor Chong as Chief Medical Officer and Tony Gibney to the Board of Directors in 2024.
• The proxy statement includes proposals for the election of directors, an advisory vote on executive compensation, and ratification of the selection of Ernst & Young LLP as independent auditors.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Clearside, highlighting progress in its clinical programs and partnerships. The focus on innovation and addressing unmet needs in retinal disease treatment contributes to a favorable sentiment.

Positives

• Suprachoroidal delivery is gaining acceptance and adoption in the ophthalmic industry.
• Clearside's SCS Microinjector has a positive safety profile.
• CLS-AX has the potential to reduce the treatment burden for wet AMD patients.
• The company has value-driving collaborations with biopharma companies.
• Clearside has a strong and experienced team.
• The company's suprachoroidal injection procedure now has a permanent Category 1 CPT code assignment, facilitating better access and insurance coverage.

Negatives

• The document does not explicitly state any negatives.

Risks

• The forward-looking statements in the proxy statement are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include uncertainties inherent in the conduct of clinical trials and reliance on third parties.

Future Outlook

Clearside expects 2024 to be a transformational year, with the ODYSSEY trial data readout potentially demonstrating CLS-AX as a valuable addition to the wet AMD treatment regimen. The company is committed to maintaining its leadership role in the suprachoroidal space.

Management Comments

• 'We believe the work we are doing has the potential to change the treatment paradigm for serious retinal diseases and leave a lasting positive impact for patients, physicians, and for you, our stockholders,' said George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer.

Industry Context

The increasing acceptance of suprachoroidal delivery addresses the need for safer and more effective drug delivery methods in ophthalmology, especially given the risks associated with intravitreal injections. Clearside's technology and partnerships position it to capitalize on this trend.

Comparison to Industry Standards

• The document mentions that currently approved therapies for wet AMD, including faricimab and high dose aflibercept, are delivered intravitreally and only offer the potential of lasting up to four months in most patients.
• Clearside believes suprachoroidal CLS-AX may extend the time between doses to meaningfully reduce the treatment burden for patients, caregivers and payors.

Management Changes

Corporate Governance

Related Party Transactions

• Bradford T. Whitmore, who owns more than 5% of Clearside's common stock, purchased 444,444 shares of common stock and warrants to purchase up to 444,444 shares of common stock at an aggregate purchase price of $599,999.40 in a registered direct offering.
• Clearside paid Alcami Corporation, Inc. approximately $1.2 million and $1.5 million in the year ended December 31, 2022 and December 31, 2023, respectively, for services relating to the manufacture of XIPERE and CLS-AX; William D. Humphries, one of Clearside's directors, became Chief Executive Officer of Alcami in June 2023.

Stakeholder Impact

• The company's progress in suprachoroidal delivery has the potential to improve outcomes for individuals living with sight-threatening diseases.
• The ODYSSEY trial data readout will be important for patients with wet AMD.
• The election of directors and advisory vote on executive compensation will impact shareholders.
• The company's relationships with physician investigators, study participants, and employees are vital to its success.

Next Steps

• The company will proceed with the Annual Meeting of Stockholders on June 20, 2024.
• Clearside will analyze the data from the Phase 2b ODYSSEY trial and plan for the CLS-AX Phase 3 clinical development program.
• The company will continue to generate data demonstrating the benefits of drug delivery with their SCS Microinjector.

Key Dates

Keywords

suprachoroidal delivery, CLS-AX, wet AMD, SCS Microinjector, XIPERE, ophthalmic, clinical trial, biopharma, retinal diseases, Clearside Biomedical